ADVERTISEMENT
Judge Tells Attys IP Testimony Is Dense, But It s Your Case
Law360, Oakland, Calif. (July 13, 2021, 10:18 PM EDT) A California federal judge presiding over a jury trial over claims Novartis infringed a Daiichi Sankyo subsidiary s billion-dollar skin cancer treatment patents questioned the usefulness of the day s dense trial testimony about chemistry and molecular structures, but told the attorneys, It s your case.
U.S. District Judge Haywood S. Gilliam Jr. s comments came during a break near the end of the second day of a jury trial that kicked off Monday with Plexxikon Inc. s counsel claiming that Novartis owes royalties for selling a drug called Tafinlar that allegedly infringes two patents, while Novartis counsel countered that the patents are invalid.
Daiichi Sankyo Company, Limited: DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU Initiated in Patients with HER2 Positive Advanced Gastric Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Oral presentation highlights data from phase 1 study of valemetostat showing promising clinical activity in patients with relapsed/refractory PTCL and ATL Pivotal phase 2 study VALENTINE-PTCL01
Pigmented Villonodular Synovitis Treatment Market In North America Is Expected To Account For Major Revenue Share Study Forecasted Till 2030- Report By Acumen Research And Consulting Acumen Research and Consulting Pune, INDIA
Acumen Research and Consulting, a global provider of market research studies, recently added a forthcoming report titled “
Pigmented Villonodular Synovitis Treatment Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2021-2030
LOS ANGELES, April 28, 2021 (GLOBE NEWSWIRE)
Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium the thin layer of tissue that lines the joints and tendons. PVNS usually affects the knee, although it can affect other joints as well.
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Celia Lin, MD, as Chief Medical Officer. Dr. Lin brings extensive clinical and industry experience in orphan diseases and multiple therapeutic areas, including nephrology and inflammation. In addition, the Company announced the appointments of Tad Thomas, PhD, as Senior Vice President (SVP) and Head of Product Development and Manufacturing and Joseph Young, MBA, as SVP of Finance.
Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical Officer